Drugs / MMF
last change Apr 2010 re-read 2 minutes ago

MMF

Developed for
acute graft versus host disease
Investigated by
Stanford University

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00350181 Aug 2006 → Aug 2007 acute graft versus host disease, leukemia, non-Hodgkin lymphoma Stanford University Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MMF ClinicalTrials.gov intervention name — accepted as the source's own label NCT00350181
Route Intravenous “Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion” NCT00350181